Penumbra, Inc.(PEN)Earnings, Financials & Key RatiosPenumbra, Inc. (PEN) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company shows a healthy 19.6% free cash flow margin, the high 70.05 P/E TTM valuation and persistent SG&A-driven margin compression warrant a cautious approach.
Penumbra, Inc. (PEN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Penumbra, Inc. (PEN) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.82vs $1.04-21.2% | $375Mvs $370M+1.2% |
| Q1 2026 | Feb 25, 2026 | $1.18vs $1.11+6.3% | $385Mvs $362M+6.5% |
| Q4 2025 | Nov 5, 2025 | $0.97vs $0.93+4.4% | $355Mvs $341M+4.0% |
| Q3 2025 | Jul 29, 2025 | $0.86vs $0.81+6.2% | $339Mvs $341M-0.6% |
Recent stock market news and headlines for Penumbra, Inc. (PEN)
ALAMEDA, Calif., July 7, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the initiation of its FORWARD study, an international, real world prospective, multi-center study.
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
PEN gains CE Mark in Europe for THUNDERBOLT, expanding stroke treatment access and advancing its global stroke care strategy.
Key metrics vs top competitors for Penumbra, Inc. (PEN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $318.31 | $12.52B | 70.42 | 17.5% | 12.66% | 13.78% | — | |
| $427.30 | $151.33B | 54.29 | 20.51% | 28.15% | 16.89% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $27.13 | $4.42B | 96.89 | 8.32% | 2.41% | 2.18% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $313.38 | $120.14B | 37.31 | 11.16% | 13.21% | 15.1% | — |
Penumbra, Inc. (PEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Penumbra, Inc. (PEN) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
May 6, 2026·SEC
Feb 25, 2026·SEC
Get notified when PEN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Penumbra, Inc. (PEN) stock FAQ — growth, dividends, profitability & financials explained
Penumbra, Inc. (PEN) reported $1.45B in revenue for fiscal year 2025. This represents a 1537% increase from $88.8M in 2013.
Penumbra, Inc. (PEN) grew revenue by 17.5% over the past year. This is strong growth.
Yes, Penumbra, Inc. (PEN) is profitable, generating $171.0M in net income for fiscal year 2025 (12.7% net margin).
Penumbra, Inc. (PEN) has a return on equity (ROE) of 13.8%. This is reasonable for most industries.
Penumbra, Inc. (PEN) generated $212.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
